Effect of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA unrectable non-small cell lung cancer (CTONG 1101, NCT01297101) on disease-free survival: A single arm, multi-center, phase II study.

被引：0
|
作者：
Chen Zhiwei
Jiang Gening
Xin, Wang
Luo, Qingquan
Lu, Shun
机构：
[1] Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Surg Oncol, Shanghai 200092, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Surg Oncol, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
[5] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18519
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE II TRIAL EVALUATING GEMCITABINE-IFOSFAMIDE-CISPLATIN AS INDUCTION TREATMENT FOR MEDIASTINOSCOPY PROVEN STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER
    Derijcke, Sofie
    Vansteenkiste, Johan
    De Leyn, Paul
    Lievens, Yolande
    Nackaerts, Kristiaan
    Dooms, Christophe
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1579 - S1580
  • [22] CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non- small cell lung cancer (EMERGING): A randomised study
    Zhong, W-Z.
    Wu, Y-L.
    Chen, K-N.
    Chen, C.
    Gu, C-D.
    Wang, Q.
    Wang, J.
    Mao, W.
    Qiao, G-B.
    Cheng, Y.
    Xu, L.
    Wang, C-L.
    Chen, M-W.
    Yang, X-N.
    Chen, H-J.
    Yang, H-H.
    Yang, J-J.
    Zhou, Q.
    ANNALS OF ONCOLOGY, 2018, 29 : 738 - 738
  • [23] A phase II trial of gemcitabine-cisplatin-paclitaxel (GDT) chemotherapy as neoadjuvant treatment of unresectable stage IIIA(N2)-IIIB non-small cell lung cancer (NSCLC):: preliminary results
    De Marinis, F
    Cappuzzo, F
    Nelli, F
    Benedetti, G
    Migliorino, MR
    Cortesi, E
    Portalone, L
    Martelli, O
    Bartolini, S
    Crinò, L
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 413 - 413
  • [24] FDG-PET in the assessment of induction chemotherapy in stage IIIA-N2 non-small cell lung cancer (NSCLC): A multi-center prospective study.
    Stroobants, SG
    Vansteenkiste, J
    Hoekstra, C
    Smit, E
    Van Zandwijk, N
    Schramel, F
    Biesma, B
    Nackaerts, K
    Van Raemdonck, D
    Lammertsma, A
    Mortelmans, L
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 301P - 302P
  • [25] Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer
    Mylonakis, N.
    Athanasiou, A.
    Ziras, N.
    Angel, J.
    Rapti, A.
    Lampaki, S.
    Politis, N.
    Karanikas, C.
    Kosmas, C.
    LUNG CANCER, 2010, 68 (02) : 240 - 247
  • [26] Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study.
    Cheng, Sida
    Wei, Zihan
    Li, Hecheng
    Li, Mingru
    Liao, Yongde
    Xu, Song
    Yan, Xiaolong
    Yang, Desong
    Yue, Dongsheng
    Zhong, Wenzhao
    Zhou, Lixin
    Chang, Geyun
    Yan, Xiang
    Yang, Fan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Sorafenib and metformin in pretreated patients with stage IV non-small cell lung cancer with a KRAS imitation: A multicenter single arm phase II study.
    Mellema, Wouter Willem
    Burgers, Sjaak A.
    Groen, Harry J. M.
    Dingemans, Anne-Marie C.
    Thunnlssen, Erik
    Heideman, Danielle
    Smit, Egbert F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] A MULTI-CENTER PHASE II RANDOMIZED STUDY OF CUSTOMIZED NEOADJUVANT THERAPY VS. STANDARD CHEMOTHERAPY (CT) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH RESECTABLE STAGE IIIA (N2) DISEASE (CONTEST TRIAL)
    Grossi, Francesco
    Rijavec, Erika
    Barletta, Giulia
    Genova, Carlo
    Sini, Claudio
    Dal Bello, Maria Giovanna
    Ratto, Giovanni Battista
    Truini, Mauro
    Merlo, Franco
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1227 - S1227
  • [29] A MULTI-CENTER PHASE II RANDOMIZED STUDY OF CUSTOMIZED NEOADJUVANT THERAPY VS. STANDARD CHEMOTHERAPY (CT) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH RESECTABLE STAGE IIIA (N2) DISEASE (CONTEST TRIAL)
    Grossi, F.
    Rijavec, E.
    Barletta, G.
    Genova, C.
    Sini, C.
    Dal Bello, M. G.
    Burrafato, G.
    Ratto, G. B.
    Truini, M.
    Merlo, D. F.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S36 - S37
  • [30] First-line icotinib in elderly patients with non-small cell lung cancer harboring active EGFR mutation: A multi-center, single-arm study.
    Shi, Chunlei
    Gu, Aiqin
    Xiong, Liwen
    Li, Yuping
    Cai, Xiaohong
    Chu, Tianqing
    Qian, Jialin
    Li, Rong
    Han, Baohui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345